118 related articles for article (PubMed ID: 19829303)
1. Indoleamine 2,3-dioxygenase+ cells correspond to the BDCA2+ plasmacytoid dendritic cells in human melanoma sentinel nodes.
Gerlini G; Di Gennaro P; Mariotti G; Urso C; Chiarugi A; Pimpinelli N; Borgognoni L
J Invest Dermatol; 2010 Mar; 130(3):898-901. PubMed ID: 19829303
[No Abstract] [Full Text] [Related]
2. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma.
Chen D; Koropatnick J; Jiang N; Zheng X; Zhang X; Wang H; Yuan K; Siu KS; Shunnar A; Way C; Min WP
J Immunother; 2014; 37(2):123-34. PubMed ID: 24509175
[TBL] [Abstract][Full Text] [Related]
3. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients.
Wu P; Wu J; Liu S; Han X; Lu J; Shi Y; Wang J; Lu L; Cao X
Clin Immunol; 2008 Oct; 129(1):40-8. PubMed ID: 18684674
[TBL] [Abstract][Full Text] [Related]
4. FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients.
Ryan M; Crow J; Kahmke R; Fisher SR; Su Z; Lee WT
Am J Otolaryngol; 2014; 35(6):689-94. PubMed ID: 25212103
[TBL] [Abstract][Full Text] [Related]
5. CD1c+ and CD303+ dendritic cells in peripheral blood, lymph nodes and tumor tissue of patients with non-small cell lung cancer.
Tabarkiewicz J; Rybojad P; Jablonka A; Rolinski J
Oncol Rep; 2008 Jan; 19(1):237-43. PubMed ID: 18097601
[TBL] [Abstract][Full Text] [Related]
6. Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control?
Chevolet I; Speeckaert R; Haspeslagh M; Neyns B; Krüse V; Schreuer M; Van Gele M; Van Geel N; Brochez L
Br J Dermatol; 2014 Nov; 171(5):987-95. PubMed ID: 24814041
[TBL] [Abstract][Full Text] [Related]
7. BDCA-2 (CD303): a highly specific marker for normal and neoplastic plasmacytoid dendritic cells.
Boiocchi L; Lonardi S; Vermi W; Fisogni S; Facchetti F
Blood; 2013 Jul; 122(2):296-7. PubMed ID: 23847189
[No Abstract] [Full Text] [Related]
8. Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma.
Ross RL; Corinaldesi C; Migneco G; Carr IM; Antanaviciute A; Wasson CW; Carriero A; Distler JHW; Holmes S; El-Sherbiny YM; McKimmie CS; Del Galdo F
Ann Rheum Dis; 2021 Jul; 80(7):920-929. PubMed ID: 33542104
[TBL] [Abstract][Full Text] [Related]
9. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes.
Gerlini G; Urso C; Mariotti G; Di Gennaro P; Palli D; Brandani P; Salvadori A; Pimpinelli N; Reali UM; Borgognoni L
Clin Immunol; 2007 Nov; 125(2):184-93. PubMed ID: 17827069
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
Speeckaert R; Vermaelen K; van Geel N; Autier P; Lambert J; Haspeslagh M; van Gele M; Thielemans K; Neyns B; Roche N; Verbeke N; Deron P; Speeckaert M; Brochez L
Eur J Cancer; 2012 Sep; 48(13):2004-11. PubMed ID: 22033321
[TBL] [Abstract][Full Text] [Related]
11. Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma.
Lee JR; Dalton RR; Messina JL; Sharma MD; Smith DM; Burgess RE; Mazzella F; Antonia SJ; Mellor AL; Munn DH
Lab Invest; 2003 Oct; 83(10):1457-66. PubMed ID: 14563947
[TBL] [Abstract][Full Text] [Related]
12. Engagement of BDCA-2 blocks TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells.
Riboldi E; Daniele R; Cassatella MA; Sozzani S; Bosisio D
Immunobiology; 2009; 214(9-10):868-76. PubMed ID: 19577819
[TBL] [Abstract][Full Text] [Related]
13. The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β and interferon γ in metastatic lymph nodes in malignant melanoma.
Pelak MJ; Śnietura M; Lange D; Nikiel B; Pecka KM
Pol J Pathol; 2015 Dec; 66(4):376-82. PubMed ID: 27003769
[TBL] [Abstract][Full Text] [Related]
14. Effect of Indoleamine 2,3 Dioxygenase Inhibitor on the Cytotoxic Activity of Tumour-infiltrating Lymphocytes.
Le Naour S; Knol AC; Pandolfino MC; Khammari A; Dréno B
Acta Derm Venereol; 2019 Nov; 99(12):1186-1187. PubMed ID: 31408178
[No Abstract] [Full Text] [Related]
15. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
Molenkamp BG; van Leeuwen PA; Meijer S; Sluijter BJ; Wijnands PG; Baars A; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2007 May; 13(10):2961-9. PubMed ID: 17504997
[TBL] [Abstract][Full Text] [Related]
16. Plasmacytoid dendritic cell subpopulations in head and neck squamous cell carcinoma.
Thiel A; Kesselring R; Pries R; Wittkopf N; Puzik A; Wollenberg B
Oncol Rep; 2011 Sep; 26(3):615-20. PubMed ID: 21687955
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of local immunosuppression in cutaneous melanoma.
Polak ME; Borthwick NJ; Gabriel FG; Johnson P; Higgins B; Hurren J; McCormick D; Jager MJ; Cree IA
Br J Cancer; 2007 Jun; 96(12):1879-87. PubMed ID: 17565341
[TBL] [Abstract][Full Text] [Related]
18. Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation.
Chen YL; Gomes T; Hardman CS; Vieira Braga FA; Gutowska-Owsiak D; Salimi M; Gray N; Duncan DA; Reynolds G; Johnson D; Salio M; Cerundolo V; Barlow JL; McKenzie ANJ; Teichmann SA; Haniffa M; Ogg G
J Exp Med; 2020 Mar; 217(3):. PubMed ID: 31845972
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell function in sentinel nodes.
Essner R; Kojima M
Oncology (Williston Park); 2002 Jan; 16(1 Suppl 1):27-31. PubMed ID: 11829280
[TBL] [Abstract][Full Text] [Related]
20. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
